Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

EQS-News: Evotec SE / Key word(s): Personnel
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

23.04.2024 / 20:40 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Hamburg, Germany, 23 April 2024:
The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT,
MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has appointed Dr Christian
Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective
01 July 2024. The election was unanimous and is the result of an extensive
selection process that began in January.

Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024,
will retire from his position at the end of June and will also not seek
re-election for his dormant Supervisory Board mandate, which expires with
the 2024 Annual General Meeting.

Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of
experience in various management positions, most recently as CEO of Mediq
and at Linde Healthcare. With his appointment, Evotec gains an experienced
CEO from the healthcare industry with extraordinary success in the
transformation of companies.

Prof. Dr Iris Löw-Friedrich, Chairperson of Evotec's Supervisory Board,
stated: "Dr Wojczewski is the ideal candidate to become the next CEO of
Evotec. His impressive track record in building and leading large,
high-performing life science organisations will be a perfect match for
Evotec's already very strong scientific teams. With his deep operational and
transformational expertise, Dr Wojczewski brings all the skills and
experience needed to adapt and shape Evotec's strategy going forward and we
wish him all the best for a successful start. On behalf of all members of
the Supervisory Board, I also express my sincere and heartfelt gratitude to
Mario for taking charge of the Company in a challenging time - as well as
for his continued leadership and for his support in the selection process."

Dr Christian Wojczewski, Evotec's designated Chief Executive Officer, said:
"I am delighted to join Evotec SE as its new CEO, and I look forward to
leading the Company into the next phase of its evolution. Evotec is a leader
in offering end-to-end R&D services and solutions to the life sciences
industry. Evotec's main success drivers are its best-in-class drug discovery
and development platforms and the quality and expertise of its dedicated
people. Together with the great people at Evotec and our partners we will
continue to drive full speed for Medicines that Matter."

Dr Mario Polywka, Evotec's Interim Chief Executive Officer, added: "Dr
Christian Wojczewski is an experienced healthcare industry executive with a
long track record of establishing high performance teams, critical top and
bottom-line focus, and strong customer orientation. I have full confidence
in his ability to lead Evotec and its smart people into a bright future."


About Dr Christian Wojczewski
Dr Christian Wojczewski (52) holds a diploma and a doctorate in chemistry
from the Johann Wolfgang Goethe University in Frankfurt am Main. From 2000,
he worked as a manager at McKinsey for companies in the pharmaceutical,
biotech and chemical industries in Europe and the USA. In 2005, he joined
Linde, the global market leader for medical and industrial gases. After
various roles within the company, Wojczewski took over as Head of Group
Strategy in 2007. During this time, he was responsible, among other things,
for the integration of both companies, the transformation into a
high-performance organisation and the strategic realignment of the Linde
Group following the acquisition of BOC. After 2010, Wojczewski took over the
management of Linde Healthcare, one of the Group's key growth drivers.
During this time, Linde Healthcare developed into the global market leader
for medical gases and services for patients with chronic respiratory
diseases. Under his leadership, sales in a total of 60 countries tripled to
more than EUR 3 bn with leading EBITDA margins within the group. In 2017,
Wojczewski joined Mediq in the Netherlands, a European leader in medical
devices and related services. As group CEO, he led the strategic review of
the portfolio, strengthened critical operating systems while streamlining
business processes, and reinforced a high-performance culture throughout the
organisation. Through a realignment and transformation, Mediq under
Wojczewski's leadership achieved an impressive turnaround with strong EBITDA
recovery and towards profitable growth. Most recently, Wojczewski has served
as a senior advisor to investors and biotech companies.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec provides high value pipeline
co-creating partnerships and solutions to all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare
stakeholders. Evotec has strategic activities in a broad range of currently
underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200
proprietary and co-owned R&D projects from early discovery to clinical
development. Evotec operates globally with more than 5,000 highly qualified
people. The Company's 17 sites offer highly synergistic technologies and
services and operate as complementary clusters of excellence. For additional
information please go to www.evotec.com and follow us on X/Twitter @Evotec
and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications,
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications,
Hinnerk.Rohwedder@evotec.com

IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG,
Volker.Braun@evotec.com


---------------------------------------------------------------------------

23.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1887571

End of News EQS News Service
---------------------------------------------------------------------------

1887571 23.04.2024 CET/CEST